Melanoma-associated antigen 2 (Cancer/testis antigen 1.2) (CT1.2) (MAGE-2 antigen)
1_MPLEQ 6_ RSQHC 11_ KPEEG 16_ LEARG 21_ EALGL 26_ VGAQA 31_ PATEE 36_ QQTAS 41_ SSSTL 46_ VEVTL 51_ GEVPA 56_ ADSPS 61_ PPHSP 66_ QGASS 71_ FSTTI 76_ NYTLW 81_ RQSDE 86_ GSSNQ 91_ EEEGP 96_ RMFPD 101_ LESEF 106_ QAAIS 111_ RKMVE 116_ LVHFL 121_ LLKYR 126_ AREPV 131_ TKAEM 136_ LESVL 141_ RNCQD 146_ FFPVI 151_ FSKAS 156_ EYLQL 161_ VFGIE 166_ VVEVV 171_ PISHL 176_ YILVT 181_ CLGLS 186_ YDGLL 191_ GDNQV 196_ MPKTG 201_ LLIIV 206_ LAIIA 211_ IEGDC 216_ APEEK 221_ IWEEL 226_ SMLEV 231_ FEGRE 236_ DSVFA 241_ HPRKL 246_ LMQDL 251_ VQENY 256_ LEYRQ 261_ VPGSD 266_ PACYE 271_ FLWGP 276_ RALIE 281_ TSYVK 286_ VLHHT 291_ LKIGG 296_ EPHIS 301_ YPPLH 306_ERALR
1: Reduces p53/TP53 transactivation function through recruitment of HDAC3 to p53/TP53 transcription sites. Also represses p73/TP73 activity. Proposed to enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. In vitro enhances ubiquitin ligase activity of TRIM28 and stimulates p53/TP53 ubiquitination by TRIM28 potentially in presence of Ubl-conjugating enzyme UBE2H. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex. May play a role in embryonal development and tumor transformation or aspects of tumor progression. In vitro promotes cell viability in melanoma cell lines. Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes. Negatively regulates acetylation and sumoylation of PML and represses PML-induced p53/TP53 acetylation and activation